Literature DB >> 15542760

Repeated exposure to the abused inhalant toluene alters levels of neurotransmitters and generates peroxynitrite in nigrostriatal and mesolimbic nuclei in rat.

A C Riegel1, S F Ali, S Torinese, E D French.   

Abstract

Toluene, a volatile hydrocarbon found in a variety of chemical compounds, is misused and abused by inhalation for its euphorigenic effects. Toluene's reinforcing properties may share a common characteristic with other drugs of abuse, namely, activation of the mesolimbic dopamine system. Prior studies in our laboratory found that acutely inhaled toluene activated midbrain dopamine neurons in the rat. Moreover, single systemic injections of toluene in rats produced a dose-dependent increase in locomotor activity which was blocked by depletion of nucleus accumbens dopamine or by pretreatment with a D2 dopamine receptor antagonist. Here we examined the effects of seven daily intraperitoneal injections of 600 mg/kg toluene on the content of serotonin and dopamine in the caudate nucleus (CN) and nucleus accumbens (NAC), substantia nigra, and ventral tegmental area at 2, 4, and 24 h after the last injection. Also, the roles of nitric oxide, peroxynitrite, and the production of 3-nitrosotyrosine (3-NT), in the CN and NAC were assessed at the same time points. Toluene treatments increased dopamine levels in the CN and NAC, and serotonin levels in CN, NAC, and ventral tegmental area. Measurements of the dopamine metabolite dihydroxyphenylacetic acid (DOPAC) further suggested a change in transmitter utilization in CN and NAC. Lastly, 3-NT levels also showed a differential change between CN and NAC, but at different time points post-toluene injection. These results point out the complexity of action of toluene on neurotransmitter function following a course of chronic exposure. Changes in the production of 3-NT also suggest that toluene-induced neurotoxicity may mediate via generation of peroxynitrite.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542760     DOI: 10.1196/annals.1316.079

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  Inhalant abuse among adolescents: neurobiological considerations.

Authors:  D I Lubman; M Yücel; A J Lawrence
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

2.  Differential effects of inhaled toluene on locomotor activity in adolescent and adult rats.

Authors:  Jeffery C Batis; John H Hannigan; Scott E Bowen
Journal:  Pharmacol Biochem Behav       Date:  2010-07-15       Impact factor: 3.533

3.  Increases in amphetamine-like discriminative stimulus effects of the abused inhalant toluene in mice.

Authors:  Scott E Bowen
Journal:  Psychopharmacology (Berl)       Date:  2006-04-07       Impact factor: 4.530

4.  Striatal dopamine dynamics in mice following acute and repeated toluene exposure.

Authors:  Aaron K Apawu; Tiffany A Mathews; Scott E Bowen
Journal:  Psychopharmacology (Berl)       Date:  2014-07-05       Impact factor: 4.530

5.  Preclinical characterization of toluene as a non-classical hallucinogen drug in rats: participation of 5-HT, dopamine and glutamate systems.

Authors:  María Teresa Rivera-García; Carolina López-Rubalcava; Silvia L Cruz
Journal:  Psychopharmacology (Berl)       Date:  2015-08-09       Impact factor: 4.530

6.  Decreased sensitivity in adolescent vs. adult rats to the locomotor activating effects of toluene.

Authors:  Scott E Bowen; Jonathan D Charlesworth; Mary E Tokarz; M Jerry Wright; Jenny L Wiley
Journal:  Neurotoxicol Teratol       Date:  2007-08-17       Impact factor: 3.763

Review 7.  Inhalant use and inhalant use disorders in the United States.

Authors:  Matthew O Howard; Scott E Bowen; Eric L Garland; Brian E Perron; Michael G Vaughn
Journal:  Addict Sci Clin Pract       Date:  2011-07

8.  Abused inhalants enhance GABA-mediated synaptic inhibition.

Authors:  M Bruce MacIver
Journal:  Neuropsychopharmacology       Date:  2009-06-03       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.